Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in Encinitas, California, specializing in the development of innovative small molecule therapeutics for inflammatory and autoimmune disorders. With a robust pipeline of drug candidates targeting pivotal disease mechanisms, Ventyx aims to address significant unmet medical needs in these challenging therapeutic areas. The company's strong focus on research and development positions it to capitalize on transformative opportunities within the dynamic biopharmaceutical industry, underscoring its commitment to delivering advanced treatment solutions. Show more

Location: 12790 EL CAMINO REAL, SAN DIEGO, CA, UNITED STATES, 92130, Suite 250, San Diego, CA, 92130, USA | Website: https://ventyxbio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.001B

52 Wk Range

$0.78 - $15.34

Previous Close

$13.95

Open

$13.96

Volume

5,046,586

Day Range

$13.94 - $13.98

Enterprise Value

818.3M

Cash

31.97M

Avg Qtr Burn

-17.51M

Insider Ownership

4.22%

Institutional Own.

70.45%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
VTX2735 (NLRP3 inhibitor) Details Recurrent Pericarditis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VTX958 (TYK2 inhibitor) Details Crohns disease	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tamuzimod (VTX002) (S1P1R modulator) Details Ulcerative colitis	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VTX3232 Details Obesity and cardiometabolic risk factors	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VTX3232 Details Parkinson's disease	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VTX958 (TYK2 inhibitor) Details Psoriatic arthritis, Psoriasis	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.